RESUMEN
Mitochondria play a key role in kidney physiology and pathology. They produce ATP to fuel energy-demanding water and solute reabsorption processes along the nephron. Moreover, mitochondria contribute to cellular health by the regulation of autophagy, (oxidative) stress responses, and apoptosis. Mitochondrial abundance is particularly high in cortical segments, including proximal and distal convoluted tubules. Dysfunction of the mitochondria has been described for tubulopathies such as Fanconi, Gitelman, and Bartter-like syndromes and renal tubular acidosis. In addition, mitochondrial cytopathies often affect renal (tubular) tissues, such as in Kearns-Sayre and Leigh syndromes. Nevertheless, the mechanisms by which mitochondrial dysfunction results in renal tubular diseases are only scarcely being explored. This review provides an overview of mitochondrial dysfunction in the development and progression of kidney tubulopathies. Furthermore, it emphasizes the need for further mechanistic investigations to identify links between mitochondrial function and renal electrolyte reabsorption.
Asunto(s)
Síndrome de Bartter , Síndrome de Kearns-Sayre , Enfermedades Renales , Humanos , Túbulos Renales/metabolismo , Túbulos Renales/patología , Síndrome de Bartter/metabolismo , Síndrome de Bartter/patología , Síndrome de Kearns-Sayre/metabolismo , Síndrome de Kearns-Sayre/patología , Enfermedades Renales/patología , MitocondriasRESUMEN
Gitelman and Bartter syndromes are rare inherited diseases that belong to the category of renal tubulopathies. The genes associated with these pathologies encode electrolyte transport proteins located in the nephron, particularly in the Distal Convoluted Tubule and Ascending Loop of Henle. Therefore, both syndromes are characterized by alterations in the secretion and reabsorption processes that occur in these regions. Patients suffer from deficiencies in the concentration of electrolytes in the blood and urine, which leads to different systemic consequences related to these salt-wasting processes. The main clinical features of both syndromes are hypokalemia, hypochloremia, metabolic alkalosis, hyperreninemia and hyperaldosteronism. Despite having a different molecular etiology, Gitelman and Bartter syndromes share a relevant number of clinical symptoms, and they have similar therapeutic approaches. The main basis of their treatment consists of electrolytes supplements accompanied by dietary changes. Specifically for Bartter syndrome, the use of non-steroidal anti-inflammatory drugs is also strongly supported. This review aims to address the latest diagnostic challenges and therapeutic approaches, as well as relevant recent research on the biology of the proteins involved in disease. Finally, we highlight several objectives to continue advancing in the characterization of both etiologies.
Asunto(s)
Síndrome de Bartter/patología , Síndrome de Gitelman/patología , Túbulos Renales Distales/patología , Asa de la Nefrona/patología , Equilibrio Hidroelectrolítico/fisiología , Síndrome de Bartter/diagnóstico , Síndrome de Bartter/genética , Síndrome de Bartter/terapia , Electrólitos/análisis , Electrólitos/uso terapéutico , Síndrome de Gitelman/diagnóstico , Síndrome de Gitelman/genética , Síndrome de Gitelman/terapia , Humanos , Hiperaldosteronismo/patología , Hipercalciuria/patología , Hipopotasemia/patología , Hiponatremia/patología , Nefrocalcinosis/patología , Defectos Congénitos del Transporte Tubular Renal/patologíaRESUMEN
Gitelman's syndrome (GS) and Bartter's syndrome (BS) are rare inherited salt-losing tubulopathies whose variations in genotype do not correlate well with either clinical course or electrolyte requirements. Using GS/BS patients as nature's experiments, we found them to be a human model of endogenous Ang II antagonism with activated Renin-Angiotensin System (RAS), resulting in high Ang II levels with blunted cardiovascular effects. These patients are also characterized by increased and directly correlated levels of both Angiotensin Converting Enzyme 2 (ACE2) and Ang 1-7. Understanding the myriad of distinctive and frequently overlapping clinical presentations of GS/BS arises remains challenging. Efforts to find a treatment for COVID-19 has fueled a recent surge in interest in chloroquine/hydroxychloroquine and its effects. Of specific interest are chloroquine/hydroxychloroquine's ability to inhibit SARS-CoV infection by impairing ACE2, the SARS-CoV2 entry point, through terminal glycosylation via effects on TGN/post-Golgi pH homeostasis. Several different studies with a GS or a BS phenotype, along with a nonsyndromic form of X-linked intellectual disability linked to a mutated SLC9A7, provide additional evidence that specific gene defects can act via misregulation of TGN/post-Golgi pH homeostasis, which leads to a common mechanistic basis resulting in overlapping phenotypes. We suggest that linkage between the specific gene defects identified in GS and BS and the myriad of distinctive and frequently overlapping clinical findings may be the result of aberrant glycosylation of ACE2 driven by altered TGN/endosome system acidification caused by the metabolic alkalosis brought about by these salt-losing tubulopathies in addition to their altered intracellular calcium signaling due to a blunted second messenger induced intracellular calcium release that is, in turn, amplified by the RAS system.
Asunto(s)
Síndrome de Bartter/genética , Infecciones por Coronavirus/tratamiento farmacológico , Síndrome de Gitelman/genética , Peptidil-Dipeptidasa A/metabolismo , Fenotipo , Neumonía Viral/tratamiento farmacológico , Enzima Convertidora de Angiotensina 2 , Inhibidores de la Enzima Convertidora de Angiotensina/farmacología , Inhibidores de la Enzima Convertidora de Angiotensina/uso terapéutico , Animales , Síndrome de Bartter/metabolismo , Síndrome de Bartter/patología , COVID-19 , Endosomas/efectos de los fármacos , Endosomas/metabolismo , Síndrome de Gitelman/metabolismo , Síndrome de Gitelman/patología , Humanos , Hidroxicloroquina/farmacología , Hidroxicloroquina/uso terapéutico , PandemiasRESUMEN
Bartter syndrome is an inherited metabolic disorder characterized by hypokalemic alkalosis and high rennin-angiotensin-aldosteronism which can occur at all ages but mainly in childhood. Classical Bartter syndrome is caused by loss-of-function variants in the gene encoding basolateral chloride channel ClC-Kb (CLCNKB), which is a common type of Bartter syndrome characterized with diverse clinical manifestations ranging from severe to very mild. This article reviews the function and mechanism of CLCNKB variants in Chinese population and the genotype-phenotype correlation of CLCNKB variants in classical Bartter syndrome.
Asunto(s)
Síndrome de Bartter , Canales de Cloruro , Pueblo Asiatico , Síndrome de Bartter/genética , Síndrome de Bartter/patología , Canales de Cloruro/genética , Estudios de Asociación Genética , Humanos , Investigación/tendenciasRESUMEN
BACKGROUND: Loss-of-function mutations in the sodium chloride (NaCl) co-transporter (NCC) of the renal distal convoluted tubule (DCT) cause Gitelman syndrome with hypokalemic alkalosis, hypomagnesemia and hypocalciuria. Since Gitelman patients are usually diagnosed around adolescence, we tested the idea that a progressive regression of the DCT explains the late clinical onset of the syndrome. METHODS: NCC wild-type and knockout (ko) mice were studied at Days 1, 4 and 10 and 6 weeks after birth using blood plasma analysis and morphological and biochemical methods. RESULTS: Plasma aldosterone levels and renal renin messenger RNA expression were elevated in NCC ko mice during the first days of life. In contrast, plasma ion levels did not differ between genotypes at age 10 days, but a significant hypomagnesemia was observed in NCC ko mice at 6 weeks. Immunofluorescent detection of parvalbumin (an early DCT marker) revealed that the fractional cortical volume of the early DCT is similar for mice of both genotypes at Day 4, but is significantly lower at Day 10 and is almost zero at 6 weeks in NCC ko mice. The DCT atrophy correlates with a marked reduction in the abundance of the DCT-specific Mg2+ channel TRPM6 (transient receptor potential cation channel subfamily M member 6) and an increased proteolytic activation of the epithelial Na+ channel (ENaC). CONCLUSION: After an initial outgrowth, DCT development lags behind in NCC ko mice. The impaired DCT development associates at Day 1 and Day 10 with elevated renal renin and plasma aldosterone levels and activation of ENaC, respectively, suggesting that Gitelman syndrome might be present much earlier in life than is usually expected. Despite an early downregulation of TRPM6, hypomagnesemia is a rather late symptom.
Asunto(s)
Síndrome de Bartter/patología , Síndrome de Gitelman/patología , Hiperaldosteronismo/patología , Túbulos Renales Distales/patología , Magnesio/metabolismo , Simportadores del Cloruro de Sodio/fisiología , Sodio/metabolismo , Animales , Síndrome de Bartter/etiología , Síndrome de Bartter/metabolismo , Síndrome de Gitelman/etiología , Síndrome de Gitelman/metabolismo , Hiperaldosteronismo/etiología , Hiperaldosteronismo/metabolismo , Túbulos Renales Distales/metabolismo , Ratones , Ratones Noqueados , Renina/metabolismo , Canales Catiónicos TRPM/metabolismoRESUMEN
Bartter and Gitelman syndromes are rare inherited tubulopathies characterized by hypokalaemic, hypochloraemic metabolic alkalosis. They are caused by mutations in at least 7 genes involved in the reabsorption of sodium in the thick ascending limb (TAL) of the loop of Henle and/or the distal convoluted tubule (DCT). Different subtypes can be distinguished and various classifications have been proposed based on clinical symptoms and/or the underlying genetic cause. Yet, the clinical phenotype can show remarkable variability, leading to potential divergences between classifications. These problems mostly relate to uncertainties over the role of the basolateral chloride exit channel CLCNKB, expressed in both TAL and DCT and to what degree the closely related paralogue CLCNKA can compensate for the loss of CLCNKB function. Here, we review what is known about the physiology of the transport proteins involved in these disorders. We also review the various proposed classifications and explain why a gene-based classification constitutes a pragmatic solution.
Asunto(s)
Síndrome de Bartter/clasificación , Canales de Cloruro/genética , Síndrome de Gitelman/clasificación , Sodio/metabolismo , Síndrome de Bartter/genética , Síndrome de Bartter/patología , Canales de Cloruro/metabolismo , Síndrome de Gitelman/genética , Síndrome de Gitelman/patología , Humanos , Túbulos Renales Distales/patología , Asa de la Nefrona/patología , Mutación , Reabsorción Renal/genéticaRESUMEN
BACKGROUND: Bartter syndrome (BS) is a rare autosomal recessive disorder of salt reabsorption at the thick ascending limb of the Henle loop, characterized by hypokalemia, salt loss, metabolic alkalosis, hyperreninemic hyperaldosteronism with normal blood pressure. BS type III, often known as classic BS (CBS), is caused by loss-of-function mutations in CLCNKB (chloride voltage-gated channel Kb) encoding basolateral ClC-Kb. CASE PRESENTATION: We reported a 15-year-old CBS patient with a compound heterozygous mutation of CLCNKB gene. She first presented with vomiting, hypokalemic metabolic alkalosis at the age of 4 months, and was clinically diagnosed as CBS. Indomethacin, spironolactone and oral potassium were started from then. During follow-up, the serum electrolyte levels were generally normal, but the patient showed failure to thrive and growth hormone (GH) deficiency was diagnosed. The recombinant human GH therapy was performed, and the growth velocity was improved. When she was 14, severe proteinuria and chronic kidney disease (CKD) were developed. Renal biopsy showed focal segmental glomerulosclerosis (FSGS) with juxtaglomerular apparatus cell hyperplasia, and genetic testing revealed a point deletion of c.1696delG (p. Glu566fs) and a fragment deletion of exon 2-3 deletions in CLCNKB gene. Apart from the CBS, ostium secundum atrial septal defect (ASD) was diagnosed by echocardiography. CONCLUSIONS: This is the first report of this compound heterozygous of CLCNKB gene in BS Children. Our findings contribute to a growing list of CLCNKB mutations associated with CBS. Some recessive mutations can induce CBS in combination with other mutations.
Asunto(s)
Pueblo Asiatico/genética , Síndrome de Bartter/genética , Canales de Cloruro/genética , Predisposición Genética a la Enfermedad/genética , Mutación , Adolescente , Síndrome de Bartter/patología , Enanismo Hipofisario/genética , Femenino , Estudios de Asociación Genética , Defectos del Tabique Interatrial , Heterocigoto , Humanos , Aparato Yuxtaglomerular , Linaje , Insuficiencia Renal CrónicaRESUMEN
The clinical, biochemical and mutation spectra of Chinese patients with Type III Bartter syndrome (type III BS), a rare autosomal recessive disorder, were investigated. A total of five unrelated Chinese patients aged 8 months to 24 years were diagnosed with type III BS via analysis of biochemical markers, including chloride, potassium and calcium, and genetic sequencing. The levels of insulinlike growth factor1 (IGF1) were evaluated via ELISA and a mutation study of cultured amniocytes was conducted for prenatal diagnosis. The child patients were admitted for polydipsia, polyuria, myasthenia and developmental delay, whereas the adult patients were hospitalized for limb numbness, polydipsia and polyuria. Nine variants in the chloride voltagegated channel Kb (CLCNKB) gene were detected, including eight sequence variants and one whole CLCNKB gene deletion. One sequence variant (c.1967T>C) was novel, whereas the remaining variants (c.595G>T, c.908A>C, c.1004T>C, c.1312C>T, c.1334_1335delCT and c.1718C>A) and the whole gene deletion had been previously reported. The whole gene deletion was frequently observed in patients with earlyonset type III BS in the present study. Two patients showed IGF1 deficiency with normal growth hormone level. All patients were treated with potassium supplementation and indometacin. The mother of one patient underwent amniocentesis during her second pregnancy; the fetus was not affected by type III BS based on screening for sequence variants, and normal development and blood electrolyte analysis following birth confirmed the diagnosis. In conclusion, five cases of type III BS in patients from mainland China were reported. Large deletions were frequently detected, particularly in earlyonset patients; isolated IGF1 deficiency was found, one novel sequence variant was identified. Prenatal diagnosis was successfully established using genetic analysis of cultured amniocytes, and may facilitate the prevention of congenital defect of type III BS in the next pregnancy.
Asunto(s)
Síndrome de Bartter/genética , Canales de Cloruro/genética , Factor I del Crecimiento Similar a la Insulina/genética , Diagnóstico Prenatal , Adolescente , Adulto , Amniocentesis/métodos , Síndrome de Bartter/diagnóstico , Síndrome de Bartter/patología , Niño , Preescolar , Femenino , Humanos , Lactante , Masculino , Mutación/genética , Fenotipo , Embarazo , Eliminación de Secuencia , Adulto JovenRESUMEN
The renal outer medullary potassium channel (ROMK; Kir1.1) plays an important role in Na+ and K+ homeostasis. ROMK knockout (KO) mice show a similar phenotype to Bartter's syndrome of salt wasting and dehydration due to reduced Na-2Cl-K-cotransporter activity but not in ROMK1 KO mice. ROMK KO mice also show hydronephrosis; however, the mechanism of this phenotype has not been understood. We have previously demonstrated a gender-sex difference in hydronephrosis and PGE2 production in ROMK KO mice. In this study we compared the gender-sex difference in bladder hypertrophy and hydronephrosis in ROMK KO mice. The bladder weight, bladder capacity, and the thickness of urothelium in male ROMK KO showed average increased two to approximately fourfold greater than wild-type (WT) mice, but there was no difference in either female or ROMK1 KO mice. The thickness of the urothelium was 648.8 ± 33.2 µm vs. 302.7 ± 16.5 µm ( P < 0.001) and the detrusor muscle 1,940.7 ± 98.9 µm vs. 1,308.2 ± 102.1 µm ( P = 0.013), respectively, in 12-mo male ROMK KO mice compared with the same age WT mice. Western blotting detected ROMK expression at 45~48 kDa, and both ROMK1 and ROMK2 mRNA were detected by quantitative PCR in the bladder. Immunofluorescence staining showed ROMK stained in the bladder, ureter, and urethra in WT but not in KO. In addition, there was a correlation between the severity of hydronephrosis and the bladder weight in male but not in female ROMK KO mice. In conclusion, ROMK expressed in the urinary tract at both protein and mRNA levels; significant enlargement and hypertrophy of the bladder may contribute to hydronephrosis in male ROMK KO mice.
Asunto(s)
Síndrome de Bartter/metabolismo , Hidronefrosis/metabolismo , Canales de Potasio de Rectificación Interna/metabolismo , Vejiga Urinaria/metabolismo , Animales , Síndrome de Bartter/genética , Síndrome de Bartter/patología , Modelos Animales de Enfermedad , Femenino , Predisposición Genética a la Enfermedad , Hidronefrosis/genética , Hidronefrosis/patología , Hipertrofia , Masculino , Ratones Noqueados , Músculo Liso/metabolismo , Músculo Liso/patología , Tamaño de los Órganos , Fenotipo , Canales de Potasio de Rectificación Interna/deficiencia , Canales de Potasio de Rectificación Interna/genética , Factores Sexuales , Uréter/metabolismo , Uréter/patología , Uretra/metabolismo , Uretra/patología , Vejiga Urinaria/patología , Urotelio/metabolismo , Urotelio/patologíaRESUMEN
Bartter syndrome (BS) type 1 is an autosomal recessive kidney disorder caused by lossoffunction mutations in the solute carrier family 12 member 1 (SLC12A1) gene. To date, 72 BS type 1 patients harboring SLC12A1 mutations have been documented. Of these 144 alleles studied, 68 different diseasecausing mutations have been detected in 129 alleles, and no mutation was detected in the remaining 15 alleles. The mutation types included missense/nonsense mutations, splicing mutations and small insertions and deletions ranging from 1 to 4 nucleotides. A large deletion encompassing a whole exon in the SLC12A1 gene has not yet been reported. The current study initially identified an undocumented homozygous frameshift mutation (c.1833delT) by Sanger sequencing analysis of a single infant with BS type 1. However, in a subsequent analysis, the mutation was detected only in the father's DNA. Upon further investigation using a nextgeneration sequencing approach, a deletion in exons 14 and 15 in both the patient and patient's mother was detected. The deletion was subsequently confirmed by use of a longrange polymerase chain reaction and was determined to be 3.16 kb in size based on sequencing of the junction fragment. The results of the present study demonstrated that pathogenic variants of SLC12A1 are heterogeneous. Large deletions appear to serve an etiological role in BS type 1, and may be more prevalent than previously thought.
Asunto(s)
Síndrome de Bartter/genética , Heterogeneidad Genética , Miembro 1 de la Familia de Transportadores de Soluto 12/genética , Alelos , Síndrome de Bartter/patología , Secuencia de Bases , Hibridación Genómica Comparativa , ADN/química , ADN/aislamiento & purificación , ADN/metabolismo , Análisis Mutacional de ADN , Exones , Genotipo , Humanos , Reacción en Cadena de la Polimerasa , Polimorfismo GenéticoRESUMEN
Gitelman's syndrome (GS) is caused by loss-of-function mutations in SLC12A3 and characterized by hypokalemic metabolic alkalosis, hypocalciuria, and hypomagnesemia. Long-term prognosis and the role of gene diagnosis in GS are still unclear. To investigate genotype-phenotype correlation in GS and Gitelman-like syndrome, we enrolled 34 patients who showed hypokalemic metabolic alkalosis without secondary causes. Mutation analysis of SLC12A3 and CLCNKB was performed. Thirty-one patients had mutations in SLC12A3, 5 patients in CLCNKB, and 2 patients in both genes. There was no significant difference between male and female in clinical manifestations at the time of presentation, except for early onset of symptoms in males and more profound hypokalemia in females. We identified 10 novel mutations in SLC12A3 and 4 in CLCNKB. Compared with those with CLCNKB mutations, patients with SLC12A3 mutations were characterized by more consistent hypocalciuria and hypomagnesemia. Patients with 2 mutant SLC12A3 alleles, compared with those with 1 mutant allele, did not have more severe clinical and laboratory findings except for lower plasma magnesium concentrations. Male and female patients did not differ in their requirement for electrolyte replacements. Two patients with concomitant SLC12A3 and CLCNKB mutations had early-onset severe symptoms and showed different response to treatment. Hypocalciuria and hypomagnesemia are useful markers in differentiation of GS and classical Bartter's syndrome. Gender, genotypes or the number of SLC12A3 mutant alleles cannot predict the severity of disease or response to treatment.
Asunto(s)
Canales de Cloruro/genética , Síndrome de Gitelman/genética , Adolescente , Adulto , Alelos , Síndrome de Bartter/genética , Síndrome de Bartter/patología , Análisis Mutacional de ADN , Femenino , Estudios de Asociación Genética , Genotipo , Síndrome de Gitelman/patología , Humanos , Hipopotasemia/etiología , Masculino , Persona de Mediana Edad , Fenotipo , Polimorfismo Genético , Miembro 3 de la Familia de Transportadores de Soluto 12/genética , Adulto JovenRESUMEN
BACKGROUND: Type I Bartter syndrome is a recessive human nephropathy caused by loss-of-function mutations in the SLC12A1 gene coding for the Na+-K+-2Cl- cotransporter NKCC2. We recently established the mutant mouse line Slc12a1I299F exhibiting kidney defects highly similar to the late-onset manifestation of this hereditary human disease. Besides the kidney defects, low blood pressure and osteopenia were revealed in the homozygous mutant mice which were also described in humans. Beside its strong expression in the kidney, NKCC2 has been also shown to be expressed in other tissues in rodents i.e. the gastrointestinal tract, pancreatic beta cells, and specific compartments of the ear, nasal tissue and eye. RESULTS: To examine if, besides kidney defects, further organ systems and/or metabolic pathways are affected by the Slc12a1I299F mutation as primary or secondary effects, we describe a standardized, systemic phenotypic analysis of the mutant mouse line Slc12a1I299F in the German Mouse Clinic. Slc12a1I299F homozygous mutant mice and Slc12a1I299F heterozygous mutant littermates as controls were tested at the age of 4-6 months. Beside the already published changes in blood pressure and bone metabolism, a significantly lower body weight and fat content were found as new phenotypes for Slc12a1I299F homozygous mutant mice. Small additional effects included a mild erythropenic anemia in homozygous mutant males as well as a slight hyperalgesia in homozygous mutant females. For other functions, such as immunology, lung function and neurology, no distinct alterations were observed. CONCLUSIONS: In this systemic analysis no clear primary effects of the Slc12a1I299F mutation appeared for the organs other than the kidneys where Slc12a1 expression has been described. On the other hand, long-term effects additional and/or secondary to the kidney lesions might also appear in humans harboring SLC12A1 mutations.
Asunto(s)
Síndrome de Bartter , Presión Sanguínea/genética , Mutación Missense , Miembro 1 de la Familia de Transportadores de Soluto 12 , Sustitución de Aminoácidos , Animales , Síndrome de Bartter/genética , Síndrome de Bartter/metabolismo , Síndrome de Bartter/patología , Huesos/metabolismo , Huesos/patología , Femenino , Homocigoto , Humanos , Hiperalgesia/genética , Hiperalgesia/metabolismo , Hiperalgesia/patología , Masculino , Ratones , Ratones Mutantes , Miembro 1 de la Familia de Transportadores de Soluto 12/genética , Miembro 1 de la Familia de Transportadores de Soluto 12/metabolismoRESUMEN
Bartter syndrome (BS) is classified into 5 genotypes according to underlying mutant genes and BS III is caused by loss-of-function mutations in the CLCNKB gene encoding for basolateral ClC-Kb. BS III is the most common genotype in Korean patients with BS and W610X is the most common CLCNKB mutation in Korean BS III. In this study, we tested the hypothesis that the CLCNKB W610X mutation can be rescued in vitro using aminoglycoside antibiotics, which are known to induce translational read-through of a nonsense mutation. The CLCNKB cDNA was cloned into a eukaryotic expression vector and the W610X nonsense mutation was generated by site-directed mutagenesis. Cultured polarized MDCK cells were transfected with the vectors, and the read-through was induced using an aminoglycoside derivative, G418. Cellular expression of the target protein was monitored via immunohistochemistry. While cells transfected with the mutant CLCNKB failed to express ClC-Kb, G418 treatment of the cells induced the full-length protein expression, which was localized to the basolateral plasma membranes. It is demonstrated that the W610X mutation in CLCNKB can be a good candidate for trial of translational read-through induction as a therapeutic modality.
Asunto(s)
Síndrome de Bartter/patología , Canales de Cloruro/metabolismo , Animales , Síndrome de Bartter/genética , Canales de Cloruro/análisis , Canales de Cloruro/genética , Clonación Molecular , Codón sin Sentido , Perros , Humanos , Inmunohistoquímica , Células de Riñón Canino Madin Darby , Microscopía Confocal , Mutagénesis Sitio-Dirigida , Proteínas Recombinantes de Fusión/análisis , Proteínas Recombinantes de Fusión/biosíntesis , Proteínas Recombinantes de Fusión/genética , TransfecciónRESUMEN
Se presenta el caso de un lactante masculino de 14 meses de edad que consulta por vómito, astenia, adinamia y palidez generalizada. Ingresa con un peso de 5.4 kg y una talla de 69 cm, marcada disminución del panículo adiposo y de la masa muscular, sin edemas. Los análisis reportaron potasio sérico 2,02 mEq/L, cloro 89,4 mEq/L, sodio 134,5 mEq/L, magnesio 2,39 mg/dl, albumina 4,52 gr/dl, creatinina sérica 0,17 mg/dl, uroanálisis con proteinuria 75 mg/dl y ecografía renal normal. Se sospecha síndrome de Bartter, por lo que se solicitan gases venosos que muestran pH 7,519, pO2 60 mmHg, pCO2 32,5 mmHg, HCO3 25,8 mmol/l, BE 3,3 mmol/L, relación calcio/creatinina en orina: 0,056, aldosterona 11,9 ngr/dl y renina total 459 pg/ml. Con estos resultados se hace el diagnóstico de SB, siendo compatible con el tipo III. Se iniciaron suplementos de potasio y diuréticos ahorradores de potasio sin lograr un adecuado aumento del potasio sérico y solo hasta iniciar indometacina este se logra corregir,al igual que la adecuada ganancia pondoestatural. A continuación se hace una revisión de la literatura sobre el síndrome de Bartter...
A case of 14-month male infant presenting with vomit, asthenia, adynamia, and generalized paleness is presented. At admission, his weight is 5.4 kg and height 69 cm, with marked reduction of his adipose pannus and muscular mass, with no edema. The tests reported serum potassium 2.02 mEq/L, chlorine 89.4 mEq/L, sodium 134.5 mEq/L, magnesium 2.39 mg/ dl, albumin 4.52 gr/dl, serum creatinine 0.17 mg/dl, urinalysis with proteinuria 75 mg/dl, and a normal renal echography. Bartter syndrome was suspected reason why venous gases were ordered which showed pH 7.519, pO2 60 mmHg, pCO2 32,5 mmHg, HCO3 25.8 mmol/l, BE 3.3 mmol/L, urine calcium/creatinine ratio 0.056, aldosterone 11.9 ngr/dl and total renin 459 pg/ml. With these results, the patient was diagnosed with BS, being compatible with type III. Potassium supplements and potassium sparing diuretics were started without achieving a proper serum potassium increase and only after starting indomethacine it could be corrected as well as the appropriate pondostatural increase. Below, there is a literature review about the Bartter syndrome Bartter, tubulopathy, hypokalemia...
Apresenta-se o caso de um lactante masculino de 14 meses de idade que consulta por vômito, astenia, adinamia e palidez generalizada. Dá entrada com um peso de 5.4 kg e uma estatura de 69 cm, marcada diminuição do panículo adiposo e da massa muscular, sem edemas. Os exames mostraram potássio sérico 2,02 mEq/L, cloro 89,4 mEq/L, sódio 134,5 mEq/L, magnésio 2,39 mg/dl, albumina 4,52 gr/dl, creatina sérica 0,17 mg/dl, uroanálise com proteinúria 75 mg/dl e ecografia renal normal. Suspeita-se de síndrome de Bartter, por isso são solicitados gases venosos que mostram pH 7,519, pO2 60 mmHg, pCO2 32,5 mmHg, HCO3 25,8 mmol/l, BE 3,3 mmol/L, relação cálcio/ creatina na urina: 0,056, aldosterona 11,9 ngr/dl e renina total 459 pg/ml. Com estes resultados é feito o diagnóstico de SB, sendo compatível com o tipo III. Iniciaram-se suplementos de potássio e diuréticos economizadores de potássio sem obter-se um aumento adequado do potássio sérico, somente ao iniciar indometacina o mesmo é corrigido, da mesma forma que o adequado desenvolvimento pondoestatural. A seguir é feita uma revisão da literatura sobre a síndrome de Bartter...
Asunto(s)
Lactante , Síndrome de Bartter , Síndrome de Bartter/diagnóstico , Síndrome de Bartter/epidemiología , Síndrome de Bartter/patología , Síndrome de Bartter/terapiaRESUMEN
Salt-losing tubulopathies with secondary hyperaldosteronism (SLT) comprise a set of well-defined inherited tubular disorders. Two segments along the distal nephron are primarily involved in the pathogenesis of SLTs: the thick ascending limb of Henle's loop, and the distal convoluted tubule (DCT). The functions of these pre- and postmacula densa segments are quite distinct, and this has a major impact on the clinical presentation of loop and DCT disorders - the Bartter- and Gitelman-like syndromes. Defects in the water-impermeable thick ascending limb, with its greater salt reabsorption capacity, lead to major salt and water losses similar to the effect of loop diuretics. In contrast, defects in the DCT, with its minor capacity of salt reabsorption and its crucial role in fine-tuning of urinary calcium and magnesium excretion, provoke more chronic solute imbalances similar to the effects of chronic treatment with thiazides. The most severe disorder is a combination of a loop and DCT disorder similar to the enhanced diuretic effect of a co-medication of loop diuretics with thiazides. Besides salt and water supplementation, prostaglandin E2-synthase inhibition is the most effective therapeutic option in polyuric loop disorders (e.g., pure furosemide and mixed furosemide-amiloride type), especially in preterm infants with severe volume depletion. In DCT disorders (e.g., pure thiazide and mixed thiazide-furosemide type), renin-angiotensin-aldosterone system (RAAS) blockers might be indicated after salt, potassium, and magnesium supplementation are deemed insufficient. It appears that in most patients with SLT, a combination of solute supplementation with some drug treatment (e.g., indomethacin) is needed for a lifetime.
Asunto(s)
Síndrome de Bartter/patología , Síndrome de Gitelman/patología , Enfermedades Renales/patología , Túbulos Renales/patología , Adulto , Aldosterona/farmacología , Aldosterona/fisiología , Síndrome de Bartter/diagnóstico , Síndrome de Bartter/terapia , Femenino , Síndrome de Gitelman/diagnóstico , Síndrome de Gitelman/terapia , Humanos , Hiperaldosteronismo/complicaciones , Hiperaldosteronismo/patología , Enfermedades Renales/diagnóstico , Enfermedades Renales/terapia , Túbulos Renales Distales/patología , Asa de la Nefrona/metabolismo , Asa de la Nefrona/patología , Nefronas/patología , Pronóstico , Sales (Química)/metabolismoRESUMEN
OBJECTIVE: To summarize the clinical characteristics of Bartter syndrome and investigate its pathogenesis. METHODS: The clinical data of 6 cases of Bartter syndrome at our hospital from November 2006 to May 2010 were analyzed retrospectively. RESULTS: The onset age of Bartter syndrome was 13-35 years old. The main symptoms included weakness (6/6), paralysis (1/6), numbness (5/6) and tetany (4/6). All patients had normal blood pressure. The biochemical tests showed persistent hypokalemia, metabolic alkalosis (6/6) and hyperreninemia. The pathological examination of deltoid muscle biopsy showed the swelling, degeneration and necrosis of myocytes and the deposition of immunocomplex in myolemma. And the pathological examination of renal biopsy showed the hyperplasia of juxtaglomerular apparatus (5/6) and the deposition of immunocomplex. All symptoms were relieved after a therapy of potassium supplementation or a combination of indomethacin, spironolactone and immunosuppressant. CONCLUSION: When such clinical features as weakness, paralysis, tetany, hypokalemic alkalosis and normotension are encountered, Bartter syndrome should be suspected. Serum electrolytes, blood gas analysis and activation of the renin-angiotensin-aldosterone system should be examined for a definite diagnosis. The treatment of choice includes potassium and magnesium supplementation or in combination with prostaglandin synthetase inhibitor, aldosterone antagonist and immunosuppressant. Immunologic mechanism may participate in the course of Bartter syndrome.
Asunto(s)
Síndrome de Bartter/patología , Adolescente , Adulto , Biopsia , Femenino , Humanos , Masculino , Sistema Renina-Angiotensina , Estudios Retrospectivos , Adulto JovenRESUMEN
Bartter syndrome (BS) Type IV, associated with a G47R mutation in the BSND gene, is known to result in a mild renal phenotype. However, we report here on three brothers with varying degrees of renal dysfunction from mild to end-stage renal disease associated with renal barttin and ClC-K expression. The brothers had histories of polyhydramnios, prematurity, polyuria, deafness, and small body size. Laboratory findings showed hypokalemic metabolic alkalosis, normotensive hyperreninemic hyperaldosteronism, and an increased urinary excretion of sodium, potassium and chloride, consistent with BS Type IV. Microscopic examination of renal tissue showed hyperplasia of cells at the juxtaglomerular apparatus with dilated atrophic tubules and tubulointerstitial fibrosis. A weak barttin signal related to CIC-K expression in the cytoplasm of tubule cells, but not the basement membrane, was noted. A sequence analysis of the BSND gene showed that the affected males were homozygous for a missense G47R mutation in exon 1 of BSND. These findings suggest that the G47R mutation results in a dramatic decrease in barttin expression, which appears to be related to the location of CIC-K being changed from the basement membrane to the cytoplasm in the tubule and might have varying effects on renal function associated with factors other than this gene.